
Featured Publications
KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation.
Lu J, Bera AK, Gondi S, Westover KD Biochemistry 2017 Dec
Chiu T, Tan J, Brenner M, Gu X, Yang M, Westover K, Strom T, Sher D, Jiang S, Zhao B Pract Radiat Oncol 2017 Nov
Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, Pulipparacharuvil S, Choy H, Timmerman RD JAMA Oncol 2017 Sep e173501
Totzke J, Gurbani D, Raphemot R, Hughes PF, Bodoor K, Carlson DA, Loiselle DR, Bera AK, Eibschutz LS, Perkins MM, Eubanks AL, Campbell PL, Fox DA, Westover KD, Haystead TAJ, Derbyshire ER Cell Chem Biol 2017 Aug 24 8 1029-1039.e7
Lu J, Harrison RA, Li L, Zeng M, Gondi S, Scott D, Gray NS, Engen JR, Westover KD Structure 2017 Jul
Multi-objective radiomics model for predicting distant failure in lung SBRT.
Zhou Z, Folkert M, Iyengar P, Westover K, Zhang Y, Choy H, Timmerman R, Jiang S, Wang J Phys Med Biol 2017 Jun 62 11 4460-4478
Covalent Guanosine Mimetic Inhibitors of G12C KRAS.
Xiong Y, Lu J, Hunter J, Li L, Scott D, Choi HG, Lim SM, Manandhar A, Gondi S, Sim T, Westover KD, Gray NS ACS Med Chem Lett 2017 Jan 8 1 61-66
Structure-guided development of covalent TAK1 inhibitors.
Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS, Ficarro SB, Mowafy S, Tam CP, Rao S, Du G, Griffin JD, Sorger PK, Marto JA, Westover KD, Gray NS Bioorg. Med. Chem. 2016 Dec
Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.
Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G, Nonami A, Griffin JD, Lauffenburger DA, Westover KD, Sorger PK, Gray NS Bioorg. Med. Chem. 2016 Dec
Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer W, Liu Y, Li L, Marto JA, Westover KD J. Biol. Chem. 2016 Nov